Citius Oncology (CTOR) Cash from Financing Activities (2023 - 2026)
Citius Oncology's (CTOR) quarterly Cash from Financing Activities came in at $18.6 million in Q2 2026, up 8163.05% quarter-over-quarter from -$231199.0 in Q1 2026.
Powered by 
Analysis
Citius Oncology (CTOR) Cash from Financing Activities (2023 - 2026) Analysis & Trends
Citius Oncology (CTOR) has reported Cash from Financing Activities for 4 consecutive years, with $18.6 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Cash from Financing Activities changed N/A year-over-year to $18.6 million in Q2 2026; TTM through Jun 2026 was $33.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $15.2 million, up 211.19% from the prior year.
- Cash from Financing Activities was $18.6 million for Q2 2026 at Citius Oncology, up from -$231199.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $18.6 million in Q2 2026 and troughed at -$24.5 million in Q1 2024.
- A 4-year average of $1.7 million and a median of $522134.0 in 2023 frame the typical range for Cash from Financing Activities.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | -1.48 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 2.34 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | -426.70 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | -1.22 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 14.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 1.30 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -181.51 Mn |
| 10 | Citius Oncology | 101.41 Mn | 101.41 Mn | 1.00 Mn | 18.64 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 18.64 Mn |
| Mar 31, 2026 | -231,199.00 |
| Dec 31, 2025 | 15.13 Mn |
| Jun 30, 2024 | 264,393.00 |
| Mar 31, 2024 | -24.55 Mn |
| Sep 30, 2023 | 779,875.00 |